Lifecare ASA: Mandatory notification of trade

Issuer

Lifecare ASA

Reference is made to the stock exchange announcement by Lifecare ASA (the
"Company") on 2 March 2026 regarding the commencement of the exercise period
for Warrants Series 1 issued in connection with the partially underwritten
rights issue completed in January 2026. Each Warrant Series 1 entitles the
holder to subscribe for one new share in the Company at an exercise price of
NOK 0.3342 per share.

The exercise period for Warrants Series 1 commenced on 2 March 2026 and
expires at 16:30 (CET) on 13 March 2026 (the "Exercise Period").

Warrants Series 1 are listed and tradable on Euronext Oslo Børs under the
ticker code "LIFEJ". Trading in Warrants Series 1 will be halted five trading
days prior to the expiry of the Exercise Period in order to facilitate
settlement of exercised warrants. Consequently, Warrants Series 1 will be
tradable up to and including today 6 March 2026 at 16:30 (CET).

Warrants Series 1 not sold on or before today at 16:30 (CET) or not exercised
on or before 13 March 2026 at 16:30 (CET) will lapse without compensation.
Holders of Warrants Series 1 who do not exercise their warrants may experience
dilution of their shareholding in the Company.

The Company has been informed that Joacim Holter, CEO and primary insider of
the Company, has purchased 600,000 Warrants Series 1 at an average price of
NOK 0.0142 per warrant.

Following this transaction, Joacim Holter holds 104,256 shares and 600,000
Warrants Series 1 in the Company.

Please see the attached notification form for further details.

This information is subject to the disclosure requirements pursuant to Article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.

About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Renete Kaarvik, CFO, [email protected], +47 94 83 82 42

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR Article 17. The information was submitted for publication,
through the agency of the contact persons set out above, at 2026-03-06 09:01
CET.

More information:
Access the news on Oslo Bors NewsWeb site

667708_260306 PDMR Attachment Joacim Holter.pdf
667708_Lifecare ASA- Mandatory notification of trade.pdf